Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum soluble CD4 levels before and after intralesional tuberculin PPD in external anogenital warts
PACTR202006534973105Phase 1Completed
- Sponsor
- Mohamed Azab
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tuberculin purified protein derivative in anogenital warts, sponsored by Mohamed Azab. Primary endpoint: Change in mean serum soluble CD4 level. Started Sep 2018; status: completed.
02
Drugs
tuberculin purified protein derivative
03
Conditions
anogenital warts
Beyond the preview
Go deeper on PACTR202006534973105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202006534973105.